Repair of chordae tendineae for rheumatic mitral valve disease. A twenty-year experience.

Sixty-two patients with rheumatic mitral valve disease (mean age 42.2 +/- 10.2 years) underwent repair of chordae tendineae between June 1974 and May 1994. Chordal shortening was done in 38 patients, fenestration in 17, resection of secondary chordae in 3, replacement in 2, and transposition in 2. In 41 patients, mitral commissurotomy was also done. Ring annuloplasty was done in all patients. The mean follow-up was 10.2 years (range 2 months to 20 years). The completeness of follow-up during the closing interval (January to July 1994) was 100%. Hospital mortality occurred in four patients (6.5%) and nine patients died during the late follow-up. The actuarial survival curve at 20 years was 65.8% +/- 10%. Six patients with mitral valve dysfunction (restenosis 4, insufficiency 2) and one with aortic valve dysfunction (structural deterioration of bioprosthesis) underwent reoperation. The actuarial curve of freedom from reoperation at 20 years for mitral valve dysfunction was 73.1% +/- 10.5%. In the 49 surviving patients, a Doppler echographic study during the closing interval showed a mean mitral valve area of 1.9 +/- 0.3 cm2. In the 43 patients with a repaired native valve, absent or trivial mitral regurgitation was documented in 35 and mild or moderate regurgitation in 8. In conclusion, repair of chordae tendineae in rheumatic mitral valve disease when feasible is a stable and safe procedure with a low prevalence of reoperation. However, the type of reconstructive operation and experience of the surgical team are major considerations in successful repair of the mitral valve.

Valve-related complications with the Hancock I porcine bioprosthesis. A twelve- to fourteen-year follow-up study.

Valve-related morbidity and mortality after heart valve replacement with the Hancock I porcine bioprosthesis has been retrospectively analyzed. From June 1974 through December 1976, 253 Hancock I bioprostheses (150 mitral and 103 aortic) were inserted in 220 selected patients who survived the operation and had follow-up until June 1989 (mean follow-up 13.5 years, with an accumulative follow-up of 2956.4 patient-years). One hundred seventeen patients had mitral valve replacement, 70 had aortic valve replacement, and 33 had combined mitral and aortic valve replacement. There were 27 thromboembolic events. The probability of being free from thromboembolism at 14 years was 81.0% +/- 7.4% for the mitral valve replacement group, 85.4% +/- 6.7% for the aortic group, and 67.1% +/- 18.4% for the mitral-aortic group. Fifteen episodes of prosthetic valve endocarditis occurred. There were 10 instances of nonstructural dysfunction (paravalvular leaks) in seven mitral valves (4.6%) and in three aortic valves (2.9%). One hundred twenty-two bioprostheses in 106 patients resulted in structural deterioration. The probability of freedom from structural deterioration at 14 years was 37.2% +/- 3.9% for the mitral group, 43.9% +/- 7.1% for the aortic group, and 30.1% +/- 8.9% for the mitral-aortic group. The logistic regression analysis between age at the time of operation and bioprosthetic life (structural deterioration-free period) demonstrates a linear regression curve (r = 0.53). There were 56 late deaths (27 patients died at reoperation). The actuarial survival rate (including hospital mortality) at 14 years was 57.2% +/- 5.4% for the entire series, with no statistically significant difference between groups. The probability of remaining free from valve-related morbidity and mortality at 14 years was 16.7% +/- 4.8% for the mitral group, 20.8% +/- 6.2% for the aortic group, and 14.0% +/- 7.0% for the mitral-aortic group. The long-term results of this series show that the clinical performance of the Hancock I porcine valve appears satisfactory during the first 6 years. The behavior of this bioprosthesis at 14 years' follow-up changes drastically, because only a minor group of patients is free from valve-related complications, justifying the restriction of its use for selected patients.

Heart valve replacement with the Hancock bioprosthesis: a 6-year review.

All patients who had a mitral or aortic Hancock valve replacement between June, 1974, and June, 1979, were reviewed. A total of 734 bioprostheses were implanted in 632 patients: 291 had mitral (MVR), 239 had aortic (AVR), and 102 had both mitral and aortic valve replacement (MVR + AVR). In 228 patients, an associated surgical procedure was necessary. It involved conservative valve operation in 205 of them. The hospital mortality was 9.6% (28) for MVR (11.5% with associated operation), 4.6% (11) for AVR (8.7% with associated operation), and 13.7% (14) for MVR + AVR (13.0% with associated operation). The follow-up period was between 1 and 6 years with a total follow-up of 934.6, 714.6, and 288.3 patient-years for MVR, AVR and MVR + AVR, respectively. The late mortality was 0.96% (9), 1.53% (11), and 2.08% (6) per patient-year for MVR, AVR, and MVR + AVR, respectively. The thromboembolic rate was 1.49%, 0.14%, and 2.08% per patient-year for MVR, AVR, and MVR + AVR, respectively. There were twelve valve failure (six wer due to rupture; four, thrombosis; one, insufficiency because of intrinsic failure; and one, stenosis without evident cause at reoperation). This represents a failure rate of 0.53%, 0.13%, and 2.08% per patient-year for MVR, AVR, and MVR + AVR, respectively. These results encourage us to continue our routine use of the glutaraldehyde xenografts as the safest valve substitute at present.

[Clinical experience with glutaraldehyde-treated porcine valvular xenografts]. / Experiencia clínica con los xenoinjertos valvulares procinos tratados con glutaraldehido.

We show the results obtained with 318 patients who had a Hancock prosthesis implanted in mitral and/or aortic positions, between June of 1974 and December of 1976. The maximal follow-up period (January 1980) was of 5.58 years, with a total follow-up of 1,129.8 patient years. The hospital rate of mortality was 10.3% (33/318), with 19 late deaths, which gives a linear index of late mortality for mitral, aortic, and mitro-aortic patients of 1.18%, 1.40%, and 3.82% patient-year respectively. The actuarial analysis of the results show a survival rate at 67 months of 89.5% for the aortics, 85% for the mitrals, and 70% for the mitro-aortics. In 12 occasions prosthesis complications developed (7 ruptures, 3 thrombosis, and 2 prosthesic disfunctions), which represents an incidence of 0.28%, 0.84%, and 2.72% patient-years for the aortic, mitral, and mitro-aortic patients respectively. Of the 15 thromboembolic accidents that developed, none had a fatal outcome, and their incidence for the aortic, mitral, and mitro-aortic patients was 0.28%, 2.19%, and 5.46% patient-year respectively. The actuarial analysis of thromboembolism shows that 98.9%, 98.3%, and 91,3% of aortic, mitro-aortic, and mitral patients respectively, were free of thromboembolism at 67 months postoperatively. The 99.3% of the patients that survived surgery have improved functionally, 80.4% having no symptoms from the cardiovascular point of view.

The surgical management of left atrial thrombosis.

A series of 122 consecutive patients with left atrial thrombosis is reviewed. Positive diagnosis was achieved in only 40 cases (36%) based on the angiographic findings and the presence of coronary fistula. The main cause of mortality and morbidity was cerebrovascular embolism. A change in our surgical technique, including the occlusion of the mitral orifice, has so far eliminated this problem.